Keyphrases
Adjuvant Therapy
100%
Melanoma
100%
Comparative Effectiveness
100%
Number-needed-to-treat
66%
Age Groups
33%
Clinical Benefit
33%
BRAF Wild Type
33%
BRAF mutant
33%
Randomized Trial
16%
Older Patients
16%
Node-positive
16%
Salvage Therapy
16%
Clinical Effect
16%
Decision-analytic Model
16%
Trametinib
16%
Sentinel Lymph Node
16%
Clinical Costs
16%
Competing Risks
16%
Medicare Reimbursement
16%
Overall Survival of Patients
16%
Pembrolizumab
16%
Reimbursement Rates
16%
Non-cancer Death
16%
Dabrafenib
16%
Markov Decision Analysis
16%
Transition Variable
16%
Medicine and Dentistry
Adjuvant Therapy
100%
Melanoma
100%
Health Care Cost
66%
Numbers Needed to Treat
66%
Overall Survival
16%
Cancer Mortality
16%
Medicare
16%
Recurrent Disease
16%
Salvage Therapy
16%
Trametinib
16%
Sentinel Node
16%
Pembrolizumab
16%
Dabrafenib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Number Needed to Treat
66%
Cancer Mortality
16%
Overall Survival
16%
Recurrent Disease
16%
Pembrolizumab
16%
Dabrafenib
16%
Trametinib
16%